Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752963 | 0.78 | ACHE (0.61) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| SCHEMBL1752980 | 0.76 | LMNA (0.55) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| SCHEMBL1752848 | 0.76 | LMNA (0.61) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| SCHEMBL1752952 | 0.76 | ACHE (0.56) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| Minaprine SCHEMBL49371 | 0.76 | ACHE (1.00) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| SCHEMBL1752816 | 0.75 | LMNA (0.60) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| Minaprine SCHEMBL124092 | 0.75 | CYP3A4 (1.00) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| Minaprine SCHEMBL124094 | 0.75 | CYP3A4 (1.00) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| SCHEMBL1752823 | 0.74 | LMNA (0.59) | ACHECYP3A4LMNACYP2D6CHRM1 | |
| Minaprine SCHEMBL124093 | 0.74 | ACHE (0.95) | ACHECYP3A4LMNACYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | U.S. GOVERNMENT (US) | 2012-06-21 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | ACHE 1/4885CYP3A4 1770/4885LMNA 2503/4885 |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | ACHE 1/4885CYP3A4 1770/4885LMNA 2503/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | ACHE 214/4885CYP3A4 1218/4885LMNA 2393/4885 |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | ACHE 172/4885CYP3A4 979/4885LMNA 2192/4885 |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | C5, PNPO, CHRNA5 | ACHE 225/4885CYP3A4 344/4885LMNA 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.